Day: April 19, 2023

Amsterdam, 19 April 2023 – Heineken N.V. (EURONEXT: HEIA; OTCQX: HEINY) publishes its trading update for the first quarter of 2023.  Key HighlightsRevenue growth 9.2% Net revenue (beia) organic growth 8.9%; per hectolitre 12.3% Beer volume -3.0% organic growth Heineken® volume growth 2.3% (5.7% excluding Russia) Gross merchandise value captured via eB2B platforms +51% Outlook for the full year unchanged; operating profit (beia) expected to grow organically mid- to high-single-digit  CEO Statement   Dolf van den Brink, Chairman of the Executive Board / CEO, commented: “We start the year with strong revenue growth driven by pricing and disciplined revenue management, while we materially increase investment behind our brands. Business performance in Europe and the Americas regions is encouraging, with...

Issuer: Scatec ASA Ex. date: 19 April 2023 Dividend amount: 1.94 per share Announced currency: NOK Payment date: 11 May 2023 This information is published in accordance with the requirements of the Euronext Issuer Rules. For further information, please contact:Andreas Austrell, VP Investor Relations, ir@scatec.com About Scatec  Scatec is a leading renewable energy solutions provider, accelerating access to reliable and affordable clean energy emerging markets. As a long-term player, we develop, build, own, and operate renewable energy plants, with 4.6 GW in operation and under construction across four continents today. We are committed to grow our renewable energy capacity, delivered by our close to 800 passionate employees and partners who are driven by a common vision of ‘Improving our Future’. Scatec is headquartered in Oslo, Norway...

VIDIDENCEL INDUCES DURABLE VACCINE–INDUCED T-CELL RESPONSES IN THE MAJORITY OF PATIENTS Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced the presentation of new clinical data from the Phase 1 ALISON ovarian cancer trial at the American Association for Cancer Research (AACR) Annual Meeting 2023. The data were presented as part of the Immunomodulatory Agents and Interventions Session held April 18, 2023 9:00 AM – 12:30 PM ET by researchers from the Department of Obstetrics and Gynaecology, University Medical Center Groningen, The Netherlands, where the ALISON trial is carried out. The poster presented at AACR is now available on Mendus website and can be accessed via the following link: https://amz.run/6boU The data presented at AACR demonstrate...

MADRID, Spain, April 19, 2023 (GLOBE NEWSWIRE) — Spanish listed company Lleida.net (OTC.US) (ALLLN.PA) (LLN.MA) registered in March 2023 a new historical record in the number of unique users of its main product, Click&Sign, which allows the certified electronic signature of contracts and any other type of documents. As of March 2023, the number of active Click&Sign circuits via API reached 1,090. This number has been increasing month by month since March 2019, when it was just 116. These circuits generated 273,327 contracts in March 2023, 34.30% more than in the same month of 2022. The growth of unique service users has remained increasing and stable for more than 30 months, which certifies the strength of Lleida.net’s technology and its level of market penetration. “The steady growth in the number of unique...

FORM 8.5 (EPT/RI)   PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”)   1.        KEY INFORMATION  (a)        Name of exempt principal trader: Investec Bank plc(b)        Name of offeror/offeree in relation to whose relevant securities this form relates:         Use a separate form for each offeror/offereeDechra Pharmaceuticals(c)        Name of the party to the offer with which exempt principal trader is connected: Investec is Advisor and Broker to Dechra Pharmaceuticals(d)        Date dealing undertaken: 18th April 2023(e)        In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?         If it is a cash offer...

Novian Technologies, a part of the Novian group which INVL Technology owns, signed an agreement with NRD Companies to acquire 100% of the shares of Rwanda-based Norway Registers Development Rwanda Ltd. (NRD Rwanda). The transaction aims to optimise asset utilisation and operating efficiency at the companies and will not currently affect the overall value of INVL Technology’s business holdings, although NRD Rwanda is expected to grow in value in the future. NRD Rwanda is a regional sales, project management and support company with projects in Rwanda, Burundi and the Democratic Republic of Congo. After acquiring the Rwanda-based company, Novian Technologies will seek to strengthen NRD Rwanda’s position in the region. Additional information: The IT services group Novian added a company in Africa to its technologies business area. On 18...

Amsterdam, 19 April 2023 – Heineken Holding N.V. (EURONEXT: HEIO; OTCQX: HKHHY) publishes its trading update for the first quarter of 2023.    Key Highlights         Revenue growth 9.2% Net revenue (beia) organic growth 8.9%; per hectolitre 12.3% Beer volume -3.0% organic growth Heineken® volume growth 2.3% (5.7% excluding Russia) Gross merchandise value captured via eB2B platforms +51% Outlook for the full year unchanged; operating profit (beia) expected to grow organically mid- to high-single-digitHeineken Holding N.V. engages in no activities other than its participating interest in Heineken N.V. and the management or supervision of and provision of services to that company.    ...

Reference is made to the announcement by Ensurge Micropower ASA (the “Company”) on 20 February 2023, wherein the Company announced the Financial Calendar for the financial Year 2023.   The Annual Report for 2022 will be published on 27 April 2023 (earlier communicated date: 20 April 2023). Contact Ståle Bjørnstad – Investor Relations E-mail: stale.bjornstad@ensurge.com (mailto:stale.bjornstad@ensurge.com) Phone: +47 99 16 76 72 This information is published in accordance with the requirements of the Continuing Obligations in Euronext Oslo Børs Rule Book II.

SAN CARLOS, Calif., April 19, 2023 (GLOBE NEWSWIRE) — Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today the pricing of an underwritten public offering of common stock and pre-funded warrants. Vaxcyte is selling 11,200,000 shares of common stock and pre-funded warrants to purchase 1,000,000 shares of common stock in the offering. The shares of common stock are being sold at a public offering price of $41.00 per share, and the pre-funded warrants are being sold at a public offering price of $40.999 per pre-funded warrant. The exercise price of the pre-funded warrants is $0.001 per share. The aggregate gross proceeds to Vaxcyte from this offering are expected to be approximately $500 million,...